Researchers identify new lung cancer detection and treatment breakthroughs

Recent medical studies have introduced significant advancements in the detection and treatment of non-small-cell lung cancer (NSCLC). A study led by NYU Langone Health demonstrates that liquid biopsies can reliably detect circulating tumor DNA (ctDNA) to predict disease recurrence. This method can identify microscopic traces of cancer months before they become visible on standard imaging scans, offering a critical window for personalized therapeutic intervention in early-stage patients.

Separately, researchers at UTHealth Houston have identified a potential new therapeutic target by studying the Golgi apparatus in specific lung cancer subtypes. The team discovered that cancer cells with extra copies of chromosome 3q produce high levels of the enzyme Phospholipase D1 (PLD1), which facilitates tumor growth and survival. In mouse models, a drug targeting this mechanism significantly slowed tumor growth without adverse health effects, suggesting that targeting the Golgi secretory machinery could be a viable treatment for various cancers.